Safety and Efficacy Study of Matrilin-3 Pretreated Autologous Adipose Derived Mesenchymal Stem Cells Implantation in Chronic Low Back Pain Patients With Lumbar Intervertebral Disc Degeneration (MANT3_ASC)

NCT05011474 PHASE1, PHASE2 UNKNOWN

To investigate the safety and efficacy of autologous adipose-derived mesenchymal stem cell spheroids pretreated with matrillin-3 in chronic low back pain patients with lumbar intervertebral disc degeneration.

Details

Lead sponsor	Inbo Han
Phase	PHASE1, PHASE2
Status	UNKNOWN
Enrolment	4
Start date	Fri Apr 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Sat Dec 31 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Patients With Chronic Low Back Pain Due to Degenerative Lumbar Disc

Interventions

• administered an autologous adipose-derived mesenchymal stem cell spheroid pretreated with matrillin 3

Countries

South Korea